C Alaric Moore (@MsSlothrop) header
C Alaric Moore (@MsSlothrop) profile picture

I’m here to learn. Current Interests (including, but not limited to): Vape hacking, terrariums, SARD/lupus tracking, UV exposure wearables, carnivorous plants

Oklahoma, USA
Joined August 2020
Photo by C Alaric Moore (@MsSlothrop)Photo by C Alaric Moore (@MsSlothrop)Photo by C Alaric Moore (@MsSlothrop)Photo by C Alaric Moore (@MsSlothrop)Photo by C Alaric Moore (@MsSlothrop)Photo by C Alaric Moore (@MsSlothrop)Photo by C Alaric Moore (@MsSlothrop)Photo by C Alaric Moore (@MsSlothrop)Photo by C Alaric Moore (@MsSlothrop)Photo by C Alaric Moore (@MsSlothrop)
Anchorage has a processing plant… maybe I should see what jobs they have.
3
1
84
*USPS processing plant.
11
Would need a rheum, derm, and neuro. But it’s a bigger place. Assuming that wouldn’t be impossible. And it would be cooooooold.
31
The summer hates me. My joints hurt, my muscles complain, my hair keeps thinning, rashes morph, nerves awry. I’m contemplating just going to the mall until these triple digits pass us. They normally have stellar AC. Does Norway need ET’s? I’m real good at getting things to work.
1
59
I built a little timelapse of one of my terrarium’s using a ESP32-CAM and a newly minted terrarium. The video quality isn’t stellar, and I’m currently ironing out various little problems, but it’s live and mostly works. alaricmoore.com/terraview/
2
91
C Alaric Moore retweeted
Additional showers/storms will be possible later this afternoon into tonight. Some of the storms could become severe with damaging winds and maybe some hail possible. #okwx #txwx
8
26
8,092
I made a case for rev 2 of the uv-sensor thing… it looks like snot. I’m calling it a “carryable” seeing as I haven’t managed to make it into something I can wear. I just carry around this box everywhere. It works. I need to design something less snotty looking.
2
69
This is what ICAP pattern AC-25 (anti-HsEg5/NuMA-2) looks like, in case you were wondering.
2
3
193
Oh damn, I deleted the link to the price I wrote talking about automating IIF readers. It makes this make more sense. alaricmoore.com/writing/ana-… It’s probably really dry material to anyone that’s not me, but whatever. I spent weeks on this grouping of words.
1
33
Over the past year while trying to find origin and solution for what has been making me sick (which we now understand is lupus, by positive tissue evidence), I have learned a lot about how ANA patterns are read by both automated instruments and human readers. The impetus for this particular piece is that I have been relatively “sero-quiet”, not negative, but while my skin and hair and clinical symptoms are screaming “this is no good now”; my serology is doing her best to keep up with the Jones’s. So, I have been searching for the allusive marker that we can track my disease with, anti-HsEg5 might be such a marker… but it’s not commercially available and there’s no guarantee I even produce it in measurable quantity. Nonetheless, this search of mine has led me to learn about this failure in the pipeline of fluoresced cells. And I find it absolutely fascinating. Perhaps a few of you will as well. alaricmoore.com/writing/ana-…
59
I posted this to Reddit, but I figure it deserves to be here too. We don’t actually know how many people have lupus, and I am confident this is harming patients: Since being diagnosed, lupus has become one of my special interests (I’m autistic, so when I say that, I mean it in the full-blown “I have read every paper I can find and have built many SARD specific tools” sense). And something keeps happening: the more I learn, the more lupus I find. In my own family: three generations of women on my father’s side, all in central Oklahoma, all with SLE. Among coworker’s family members or themselves. Among friends and friends of friends. Some of my clinicians. Everywhere I look, lupus, or some flavor of it (MCTD, DM, Incomplete lupus, cutaneous, UCTD.. you get the drift) seems to exist in one way or another. For a while I wondered if this was just the Baader-Meinhof effect, you buy a red car and suddenly every car on the road is red. But then I started reading how SLE prevalence is actually measured in this country, and I realized: it might not be that I’m suddenly noticing lupus everywhere. It might be that lupus actually is everywhere, and we’ve just never properly counted. I’m posting this because of the recent thread here about racial prevalence of lupus after that interview between those two people I’ve never heard of were posted saying incorrect things about lupus prevalence. There were some good points made in the thread, but I think the conversation was missing a critical piece: the numbers we’re all arguing about are far less solid than most people realize, and that uncertainty isn’t just academic; it’s shaping how our doctors and society views us, and ultimately shapes health outcomes down the line. Here’s the situation: SLE is not a nationally reportable disease. Unlike cancer, TB, or HIV, no one is required to report new lupus cases to any central database. There is no national lupus count. What we have instead are estimates, built from a small number of regional registries. The number most commonly cited in research, about 204,000 Americans with SLE, comes from a 2021 meta-analysis (Izmirly et al., Arthritis & Rheumatology) that pooled data from five CDC-funded registries. Those registries covered portions of Georgia, Michigan, California, New York, and the Indian Health Service. The data was collected between 2002 and 2009, then extrapolated to the 2018 census. The authors themselves describe this as likely representing a lower bound. The older “1.5 million” number the Lupus Foundation uses? That comes from a 1994 telephone marketing survey. Neither of these is a count. They’re estimates built on estimates. And when a different methodology is used, a nationally representative population survey (MEPS, 2016–2018), the number roughly doubles. That study found a prevalence of 195 per 100,000, which translates to around 490,000 adults with SLE. Why does this gap exist? I propose several reasons: The registries used ACR classification criteria to define cases. These criteria were designed for research classification, not clinical diagnosis. The Lupus Foundation itself has noted that at one major academic medical center, only half of patients actively receiving lupus treatment met those criteria at that time, or ever. So the registries were structurally designed to miss roughly half the population being treated. The registries also excluded cutaneous lupus, incomplete lupus, and drug-induced lupus entirely. And they covered parts of five states, not the country. Why this matters for you, personally: When a doctor “knows” that lupus is rare and primarily affects young Black women, that shapes how they evaluate every patient who walks in. A white woman with fatigue and joint pain gets worked up differently than a Black woman with the same symptoms. An older patient gets told it’s “probably not lupus.” A man doesn’t even get considered.
3
1
203
And then we can’t forget about the general issue with many, not all, clinicians not trusting the reporting of pain and vague symptoms from women of any race or economic background. But we can’t actually say with confidence how lupus prevalence breaks down by race or geographic region, because the counting methodology itself has racial blind spots. The IHS registry in Oklahoma, covering Native American patients, validated fewer than 10% of potential cases, compared to 35-40% in other regions (Ferucci et al. 2014, Arthritis & Rheumatology). Was that because Native Americans in Oklahoma don’t get lupus? No. It was because IHS Oklahoma had limited rheumatology infrastructure at the time the data was collected. That wouldn’t exist until 2011. They conducted their census in 2009. We observe disparities in every study that’s been done. Black women consistently show higher rates, and by all accounts that demographic appears to have more aggressive disease. But we cannot say how much of the observed disparity is biology versus access, detection, and counting methodology, because the counting itself is incomplete. The perception that lupus is rare is not a fact. It’s an artifact of not conducting an accurate census. And that artifact has clinical consequences every time one of us sits in an exam room and gets told our symptoms are probably anxiety. This may be contributing to the 6-7 year average for diagnostic delay. Which then in turn leaves more time for organ damage accrual and missed opportunities for earlier interventions, which are often less costly and allow patients to remain working and stay off disability for longer periods. I am not saying this is a doctor problem or a bureaucratic problem or a patient problem or a race or sex problem. This is a simple numbers problem. We need to start reporting cases of SLE (and other lupus-associated diseases) to a national registry. This will improve health outcomes, research funding, and save lives of those who are caught far beyond just joint aches and rashes. Sources: •Izmirly et al. 2021, “Prevalence of SLE in the United States” — Arthritis & Rheumatology 73(6):991-996 stacks.cdc.gov/view/cdc/1068… •Ferucci et al. 2014, “Prevalence and Incidence of SLE in a Population-Based Registry of AI/AN People, 2007-2009” — Arthritis & Rheumatology 66(9):2494-2502 acrjournals.onlinelibrary.wi… •Engel-Nitz et al. 2022, “Real-world burden of SLE in the USA: MEPS 2016-2018” — Lupus Science & Medicine 9:e000699 pubmed.ncbi.nlm.nih.gov/3560… •Engel-Nitz et al. 2021, “Prevalence of SLE in the United States: Updated Population Representative Estimates from MEPS 2016-2018” — ACR Meeting Abstracts acrabstracts.org/abstract/pr… •Engel-Nitz et al. 2021, “Racial Disparities in US Adults with SLE: Prevalence, Quality of Life, Comorbidities and Healthcare Costs” — ACR Meeting Abstracts acrabstracts.org/abstract/ra… •CDC, “Detailed Fact Sheet: Systemic Lupus Erythematosus” (confirms SLE is not a reportable disease and recent national estimates are not available) cdc.gov/lupus/media/pdfs/nat… •Lupus Foundation of America, “Why It’s Difficult to Determine Exactly How Many People Are Living with Lupus in the U.S.” (documents ACR criteria missing ~50% of treated patients) lupus.org/resources/how-many… •Gatto et al. 2023, “The Global Epidemiology of SLE: Narrowing the Knowledge Gaps” — Rheumatology 62(S1):i4-i16 academic.oup.com/rheumatolog… •Duarte-García et al. 2022, “The Rising Incidence and Prevalence of SLE” — Annals of the Rheumatic Diseases (43-year Olmsted County data showing increasing incidence) stacks.cdc.gov/view/cdc/1328…
103
One of my tilandsia is blooming!
2
53
Um, making a case is hard. This is my futile attempt with acrylic and silicon, and because I don’t have normal super glue, nail glue. It’s the same but it comes in a pink bottle. I might need to learn how to make a design to 3D print a case.
8
10
662
And yes, I have a husky, and it’s shedding season. Actually, that’s just all year, it’s *extra* shedding season
2
37
This is my pile of breakouts that has a slimmer profile than my earlier pile of breakouts, that does succeed at its designed purpose of sampling UVA/UVB light and syncing with over WiFi/BLE to drop it all in my pi4 flask server for my flare forecasting app.
1
2
49
The first “case”, its disguised as e-waste. It’s an aesthetic, trust me.
1
32
Just had a lovely evening talking about sardine tracker with a fellow luper. Building out the android companion app for her. I’m so curious how the model will perform for her, excited too!
1
35